Beneficence and non-maleficence Sample Clauses

Beneficence and non-maleficence. As the principles of beneficence and non-maleficence are closely related, they are discussed together in this section. Beneficence involves balancing the benefits of treatment against the risks and costs involved, whereas non-maleficence means avoiding the causation of harm. As many treatments involve some degree of harm, the principle of non-maleficence would imply that the harm should not be disproportionate to the benefit of the treatment. Respecting the principles of beneficence and non- maleficence may in certain circumstances mean failing to respect a person’s autonomy i.e. respecting their views about a particular treatment. For example, it may be necessary to provide treatment that is not desired in order to prevent the development of a future, more serious health problem. The treatment might be unpleasant, uncomfortable or even painful but this might involve less harm to the patient than would occur, were they not to have it. In cases where the patient lacks legal competence to make a decision, medical staff are expected to act in the best interests of the patient. In doing so, they may take into account the principles of beneficence and non-maleficence. However, it would be helpful for medical staff in such cases, if the patient lacking capacity had made an advance directive. Nevertheless, as will be seen in the following section on “the position of advance directives alongside current wishes”, problems may arise when there is a conflict between what a person requested in an advance directive and what in the doctor’s view is in their best interests, particularly in cases where it is no longer clear that the person in question would still agree with the decision previously made. In Western medicine, the principles of beneficence and non-maleficence derive historically from the doctor-patient relationship, which for centuries was based on paternalism. In the last few decades, there has been a change in the doctor-patient relationship involving a move towards greater respect for patients’ autonomy, in that patients play a more active role in making decisions about their own treatment (Xxxxxx, 2003). According to Xxx (2002), this is not the same in non-Western medicine. She explains that in Islamic medical ethics, a greater emphasis is placed on beneficence than on autonomy especially at the time of death. Xxxxx and Xxxxx (2002), who investigated the existence of the four principles in the Islamic tradition by examining the works of Xxxxxxx, a promin...
AutoNDA by SimpleDocs
Beneficence and non-maleficence. The term beneficence has been used in literature on biomedical ethics since about 1975 to refer to the principle of balancing the risk of harm to a patient with the possible benefits which might occur as a result of a particular treatment or course of action (Stanford University, 2008). As such, it is not limited to non-maleficence which simply involves not causing harm. This is important as sometimes a certain degree of pain, discomfort or risk is necessary in order to prevent a more serious (and perhaps more painful) condition. When deciding on end-of-life treatment for people with dementia, the risk of developing more serious conditions is perhaps less relevant due to the extremely limited life expectancy of patients. The risks and potential burden involved in any particular treatment are also subject to individual as well as medical interpretation and may be linked in some cases to judgements about the value and quality of life. In the case of palliative care of people with dementia, there is a danger that blanket judgments will be made about the value or quality of life of people with advanced stages of dementia, that insufficient information will be sought about patients’ wishes and that opinions about the value or quality of life may be projections of decision makers’ own feelings about such issues. Justice/equity The principle of “justice/equity” could be described as the moral obligation to act on the basis of fair adjudication between competing claims. As such, it is linked to fairness, entitlement and equality. In health care ethics, this can be subdivided into three categories: fair distribution of scarce resources (distributive justice), respect for people’s rights (rights based justice) and respect for morally acceptable laws (legal justice) (Xxxxxx, 1994). Palliative care services are not particularly well-developed throughout Europe and access to existing services is often restricted to people with cancer. Yet people who are dying with/from dementia are every much as entitled to palliative care as people with cancer.

Related to Beneficence and non-maleficence

  • Permitted License Uses and Restrictions (a) This Order Form Supplement allows you, as an authorized User under the Master Subscription Agreement, to use the Software on any Supported Device and on no other devices.

  • Non-Synchronous Generation The Interconnection Customer shall design its Small Generating Facility to maintain a composite power delivery at continuous rated power output at the high-side of the generator substation at a power factor within the range of 0.95 leading to 0.95 lagging, unless the NYISO or the Transmission Owner in whose Transmission District the Small Generating Facility interconnects has established a different power factor range that applies to all similarly situated non-synchronous generators in the control area or Transmission District (as applicable) on a comparable basis, in accordance with Good Utility Practice. This power factor range standard shall be dynamic and can be met using, for example, power electronics designed to supply this level of reactive capability (taking into account any limitations due to voltage level, real power output, etc.) or fixed and switched capacitors, or a combination of the two. This requirement shall only apply to newly interconnecting non-synchronous generators that have not yet executed a Facilities Study Agreement as of September 21, 2016.

  • Gouvernement des États-Unis Le logiciel et la documentation constituent des « Commercial Items » (éléments commerciaux), tel que ce terme est défini dans la clause 48 C.F.R. (Code of Federal Rules) §2.101, consistant en « Commercial Computer Software » (logiciel) et « Commercial Computer Software Documentation » (documentation), tels que ces termes sont utilisés dans les clauses 48 C.F.R. §12.212 ou 48 C.F.R. §227.7202. Conformément à la clause 48 C.F.R. §12.212 ou 48 C.F.R. §227.7202-1 à 227.7202-4, le « Commercial Computer Software » et le « Commercial Computer Software Documentation » sont fournis sous licence au gouvernement des États-Unis (a) uniquement comme « Commercial Items » et (b) uniquement accompagnés des droits octroyés à tous les autres utilisateurs conformément aux termes et conditions ci-inclus. Droits non publiés réservés en vertu de la législation des droits d’auteur en vigueur aux États-Unis.

  • Transfer of License Notwithstanding the provisions of conditions 17.1 and 17.2, if Customer sells or transfers the Equipment in which the Software operates, Kodak shall offer to license the Software, and to provide services, to any bona fide end user (“Transferee”) pursuant to Kodak’s then current standard terms, conditions and fees, provided that the Transferee is not considered, in Kodak’s discretion, a competitor of Kodak or its parent, affiliates or subsidiaries. To the extent that the Software is licensed to a Transferee in accordance with this condition, Customer’s license to use the Software shall be deemed terminated. Kodak shall offer to provide de-installation services for the Customer and re-installation and certification for the Equipment and Software and services for the Transferee at Kodak’s then current applicable fees.

  • License Types The following License Types may be offered with respect to individual Software products or product families. Additional license types may be specified with respect to certain products or product groups as set forth in the Product Specific Terms. The License Type will be specified in an LSDA.

  • Single User License A Single-User license is for a named individual who is identified as the only Authorized User. This user is not permitted to re-assign, transfer, or sublicense the software, except as described in Section 5, Transfer. This user may install and use the software on up to three computers, as long as the single-user Customer is the sole user of the software. If the computer on which this Software is loaded is attached to a network, this Software must not be accessible by any other user on such network. Single-user licenses may not be installed or used in a virtualized environment in order to or in a manner that circumvents the single user license type.

  • License Transfer You may not transfer the software to a third party without Microsoft’s prior written consent. If permitted, there may be additional charges for transferring the software to a third party.

  • SECTION 907 - VEHICLE CONFIGURATIONS AND RESTRICTIONS The SADT on the section shall be understood to be 1,500.

  • Utilisations permises de la licence et restrictions A. Licence de logiciel Apple préinstallé ou copie unique. Sous réserve des conditions générales de cette Licence, et à moins que vous ayez acquis le logiciel Apple dans le Mac App Store, par le biais d’un téléchargement automatique ou dans le cadre d’une licence ou maintenance de volume ou tout autre accord écrit passé avec Apple, une licence de non-exclusivité limitée vous est accordée pour installer, utiliser et exécuter un (1) seul exemplaire du logiciel Apple sur un seul ordinateur Apple à la fois. Par exemple, les termes de la présente Licence à copie unique s’appliquent à vous si vous avez acquis le logiciel Apple préinstallé sur un matériel de marque Apple.

  • License Type Your license to a Product will be under a Named User or CPU license type, as specified on an order. Each Named User license to a Product entitles a Named User to access and use that Product in one production environment and up to two non-production environments. Each CPU license to a Product entitles you to assign the Product to a single CPU in one production environment and up to two non-production environments, for use in support of an unspecified number of Named Users.

Time is Money Join Law Insider Premium to draft better contracts faster.